FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of June 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca enters into collaboration with CSPC
13 June
2025
AstraZeneca enters strategic collaboration with CSPC
Pharmaceuticals focused on AI-enabled research
AstraZeneca has entered a strategic research collaboration with
Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working
together on high priority targets, the collaboration aims to
advance the discovery and development of novel oral candidates,
with the potential to treat diseases across multiple
indications.
Under the terms of the agreement, AstraZeneca and CSPC agree to
discover and develop pre-clinical candidates for multiple targets
with the potential to treat diseases across chronic indications,
including a pre-clinical small molecule oral therapy for
immunological diseases.
Sharon Barr, Executive Vice President and Head of
BioPharmaceuticals R&D said: "This strategic research
collaboration underscores our commitment to innovation to tackle
chronic diseases which impact over two billion people globally.
Forming strong collaborations allows us to leverage our
complementary scientific expertise to support the rapid discovery
of high-quality novel therapeutic molecules to deliver
the next-generation medicines."
The research will be carried out by CSPC, in Shijiazhuang City and
will utilise their AI-driven, dual-engine efficient drug discovery
platform. This platform uses AI technology to analyse the binding
patterns of target proteins with existing compound molecules,
conduct targeted optimization, with the aim of selecting highly
effective small molecules with excellent
developability.
The collaboration furthers AstraZeneca's presence in China
following the $2.5bn investment in
Beijing announced earlier
this year and strengthens the ongoing collaboration with
CSPC.
Financial considerations
Under the terms of the agreement, CSPC will receive an upfront
payment of $110 million, and is also eligible to receive up to
$1.62 billion in potential development milestone payments and up to
$3.6 billion in sales milestone payments, plus potential single
digit royalties based on annual net sales of the
products.
Under the agreement, AstraZeneca will have rights to exercise
options for exclusive licenses to develop and commercialise
worldwide candidates identified under this agreement.
Notes
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 13 June 2025
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|